# Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

> **NCT03915678** · PHASE2 · RECRUITING · sponsor: **Institut Bergonié** · enrollment: 247 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Pancreatic Cancer
- Virus-associated Tumors
- Non Small Cell Lung Cancer
- Melanoma
- Bladder Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Association atezolizumab + BDB001 + RT
- **DRUG:** Association atezolizumab + BDB001+ RT
- **DRUG:** Association atezolizumab + BDB001+ RT
- **DRUG:** Association atezolizumab + BDB001 + RT
- **DRUG:** Association atezolizumab + BDB001 + RT
- **DRUG:** Association atezolizumab + BDB001 + RT

## Key facts

- **NCT ID:** NCT03915678
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-31
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 247 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915678, "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03915678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*